LI-COR, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 1971-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.licor.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Open-label Study to Evaluate Nerindocianine as a Surgical Aid in Ureter Delineation During Minimally Invasive Surgery
Phase 2
Withdrawn
- Conditions
- Intraoperative Ureter Injury
- Interventions
- Drug: Nerindocianine for injection
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Li-Cor, Inc.
- Registration Number
- NCT04636567
- Locations
- πΊπΈ
Cleveland Clinic Florida, Weston, Florida, United States
πΊπΈCarolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery
Phase 1
Completed
- Conditions
- Intraoperative Ureter Injury
- Interventions
- Drug: Nerindocianine for Injection
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Li-Cor, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03106038
- Locations
- πΊπΈ
UAB Women & Infants Center, Birmingham, Alabama, United States
News
No news found